Ridaura / Auranofin: Overview

Modified on 2009/10/14 21:49 by admin
Auranofin, known under the brand name Ridaura, is prescribed for the treatment of rheumatoid arthritis in adults who have had insufficient response to one or more nonsteroidal anti-inflammatory drugs. Ridaura slows the progress of the disorder, preventing further damage to joints. Therapeutic results are not seen immediately. Thus, the benefits of Ridaura, a gold-containing compound, may not be seen for up to six months.

Side effects of Ridaura use include, but may not be limited to, bleeding, bronchitis, fever, rash, bruising, gastrointestinal disorders such as loose stools, abdominal pain and nausea and decreases in white and red blood cell counts. Ridaura was approved by the U.S. Food and Drug Administration (FDA) in 1985 and is manufactured by Connetics Corporation.

A black box warning indicates that because Ridaura contains gold, a possibility of gold toxicity exists. Recommended laboratory work should be extensively reviewed before a physician writes a prescription for the medication. Only experienced doctors in chrysotherapy (treatment by injection of gold salts) should administer Ridaura.

See your doctor if you have experienced an adverse reaction after being administered Ridaura. In addition, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Arthritis Drugs
  2. Bronchitis: Overview
  3. Bruises: Overview
  4. Excessive Bleeding: Overview
  5. Nausea: Overview
  Name Size